PBS Biotech: Challenges of Scalable Manufacturing of Allogeneic Cell Therapies
Friday, May 31, 2024 07:00 AM - 08:00 AM
Room 217-219
Corporate Session
Chair
• Jordan M. Greenberg, PhD, Senior Manager, MSAT, Shoreline Biosciences, USA
Speakers
• Breanna Borys, PhD, Bioprocess Scientist, Bioprocess R&D, PBS Biotech, USA
Allogeneic cell therapies offer an off-the-shelf solution that can help alleviate logistical and economical challenges associated with autologous therapies; however, the cell therapy industry has largely been built to support autologous therapies. As the scale of manufacturing grows from a few liters to 100s of liters challenges in how to perform media exchanges, wash/concentrate protocols, fill/finish and cryopreservation begin to emerge, and new methodologies and technologies are required to manufacture at a commercial scale. Thinking with the end in mind, drug developers would be wise to consider scalability early in the development of their processes to avoid costly development and comparability work down the road. In this session we will discuss current bottlenecks in allogeneic cell therapy manufacturing and strategies to help early phase developers operate with the end goal of creating a commercially viable product.
• Jordan M. Greenberg, PhD, Senior Manager, MSAT, Shoreline Biosciences, USA
Speakers
• Breanna Borys, PhD, Bioprocess Scientist, Bioprocess R&D, PBS Biotech, USA
Allogeneic cell therapies offer an off-the-shelf solution that can help alleviate logistical and economical challenges associated with autologous therapies; however, the cell therapy industry has largely been built to support autologous therapies. As the scale of manufacturing grows from a few liters to 100s of liters challenges in how to perform media exchanges, wash/concentrate protocols, fill/finish and cryopreservation begin to emerge, and new methodologies and technologies are required to manufacture at a commercial scale. Thinking with the end in mind, drug developers would be wise to consider scalability early in the development of their processes to avoid costly development and comparability work down the road. In this session we will discuss current bottlenecks in allogeneic cell therapy manufacturing and strategies to help early phase developers operate with the end goal of creating a commercially viable product.
SPONSORED BY:
